Last reviewed · How we verify
[14C]-BAY2927088 oral solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-BAY2927088 oral solution ([14C]-BAY2927088 oral solution) — Bayer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-BAY2927088 oral solution TARGET | [14C]-BAY2927088 oral solution | Bayer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-BAY2927088 oral solution CI watch — RSS
- [14C]-BAY2927088 oral solution CI watch — Atom
- [14C]-BAY2927088 oral solution CI watch — JSON
- [14C]-BAY2927088 oral solution alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-BAY2927088 oral solution — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-bay2927088-oral-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab